Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt-autophagy pathway.

Human cell - 1 Jul 2023

Yin Le, Zhang Qingyang, Xie Sisi, Cheng Zhao, Li Ruijuan, Zhu Hongkai, Yu Qian, Yuan Huan, Wang Canfei, Peng Hongling, Zhang Guangsen

Abstract excerpt

Currently, therapy for Chronic Myeloid Leukemia (CML) patients with the T315I mutation is a major challenge in clinical practice due to its high degree of resistance to first- and second-generation Tyrosine Kinase Inhibitors (TKIs). Chidamide, a Histone Deacetylase Inhibitor (HDACi) drug, is currently used to treat peripheral T-cell lymphoma. In this study, we investigated the anti-leukemia effects of chidamide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Autophagy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Fusion Proteins, bcr-abl

Share to Histone Deacetylase Inhibitors

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Source

Identifiers

PMID: 37222919
DOI: 10.1007/s13577-023-00919-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt-autophagy pathway.PMID 37222919Read ↗

Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.Semantic proximity Read ↗

Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancySemantic proximity Read ↗

HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.Semantic proximity Read ↗

Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in ChinaSemantic proximity Read ↗

HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathwaySemantic proximity Read ↗

CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagySemantic proximity Read ↗

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid MalignanciesSemantic proximity Read ↗

Potential role of autophagy induced by FLT3-ITD and acid ceramidase in acute myeloid leukemia chemo-resistance: new insights.Semantic proximity Read ↗

Combination of axitinib with dasatinib improves the outcome of a chronic myeloid leukemia patient with BCR-ABL1 T315I mutation.Semantic proximity Read ↗

PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.Semantic proximity Read ↗

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.Semantic proximity Read ↗

Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.